Buprenorphine 8 mg to Oxycodone Equivalency
There is no established direct conversion factor between buprenorphine (Suboxone) 8 mg and oral oxycodone in clinical guidelines or FDA labeling, and attempting such a conversion is clinically inappropriate because buprenorphine is a partial opioid agonist with fundamentally different pharmacology than full agonists like oxycodone.
Why Direct Conversion Is Not Possible
Pharmacological Differences
Buprenorphine acts as a partial agonist at mu-opioid receptors with a ceiling effect for respiratory depression, while oxycodone is a full agonist with linear dose-response characteristics 1, 2
The partial agonist properties of buprenorphine mean it can actually block or attenuate the effects of full agonist opioids like oxycodone, rather than simply adding to them 3
Research demonstrates that buprenorphine/naloxone produces dose-related reduction in the subjective and reinforcing effects of acutely administered oxycodone, confirming the antagonistic interaction between these medications 3
Clinical Context Matters
Standard opioid conversion tables (which provide factors like morphine to oxycodone at 1.5:1) explicitly do not include buprenorphine because it doesn't follow the same equianalgesic principles 4, 5
The CDC and NCCN guidelines on opioid conversion discuss morphine, oxycodone, hydromorphone, methadone, and fentanyl, but notably exclude buprenorphine from equianalgesic conversion calculations 6
What the Evidence Shows
Buprenorphine's Unique Profile
Buprenorphine has high receptor affinity but low intrinsic activity, meaning it binds tightly to opioid receptors but produces less maximal effect than full agonists 1
When patients maintained on buprenorphine/naloxone (doses of 2/0.5 mg to 16/4 mg daily) were given oxycodone 10-60 mg, oxycodone produced diminished subjective effects and failed to serve as a reinforcer, unlike in opioid users not on buprenorphine 3
Clinical Implications
Switching from full agonist opioids to buprenorphine requires specialized induction protocols (traditional withdrawal-based, microdosing, or bridging strategies) precisely because direct dose equivalency doesn't exist 7
Buprenorphine is now considered a first-line treatment for opioid use disorder, not as an analgesic equivalent to oxycodone 8
Critical Pitfalls to Avoid
Do not attempt to calculate a simple milligram-to-milligram conversion between these medications as you would with morphine and oxycodone 6, 5
Do not assume that because a patient takes buprenorphine 8 mg, they can be switched to any specific dose of oxycodone without risk of either inadequate effect or precipitated withdrawal 7
If transitioning from buprenorphine to oxycodone for pain management, this requires careful clinical assessment and cannot be done using standard conversion tables 3
When This Question Arises Clinically
For Pain Management
- If a patient on buprenorphine for opioid use disorder develops acute pain requiring opioid analgesia, higher doses of full agonists may be needed due to buprenorphine's receptor blockade, or alternative non-opioid strategies should be prioritized 3
For Opioid Use Disorder Treatment
Buprenorphine 8-16 mg daily is the evidence-based dose range for treating opioid use disorder, regardless of what full agonist dose the patient was previously using 1, 8
The 2024 Canadian guideline confirms that buprenorphine and methadone are equally effective first-line options for opioid use disorder, with dosing based on clinical response rather than prior opioid equivalents 8